<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" VersionID="2" Owner="NLM">
      <PMID Version="2">34707085</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>11</Month>
        <Day>08</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>11</Month>
        <Day>08</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2059-3635</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>6</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Oct</Month>
              <Day>27</Day>
            </PubDate>
          </JournalIssue>
          <Title>Signal transduction and targeted therapy</Title>
          <ISOAbbreviation>Signal Transduct Target Ther</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Myeloid cells in COVID-19 microenvironment.</ArticleTitle>
        <Pagination>
          <StartPage>372</StartPage>
          <MedlinePgn>372</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">372</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1038/s41392-021-00792-0</ELocationID>
        <Abstract>
          <AbstractText>Varying differentiation of myeloid cells is common in tumors, inflammation, autoimmune diseases, and metabolic diseases. The release of cytokines from myeloid cells is an important driving factor that leads to severe COVID-19 cases and subsequent death. This review briefly summarizes the results of single-cell sequencing of peripheral blood, lung tissue, and cerebrospinal fluid of COVID-19 patients and describes the differentiation trajectory of myeloid cells in patients. Moreover, we describe the function and mechanism of abnormal differentiation of myeloid cells to promote disease progression. Targeting myeloid cell-derived cytokines or checkpoints is essential in developing a combined therapeutic strategy for patients with severe COVID-19.</AbstractText>
          <CopyrightInformation>© 2021. The Author(s).</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Qin</LastName>
            <ForeName>Guohui</ForeName>
            <Initials>G</Initials>
            <AffiliationInfo>
              <Affiliation>Biotherapy Center and Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Liu</LastName>
            <ForeName>Shasha</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Biotherapy Center and Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y" EqualContrib="Y">
            <LastName>Yang</LastName>
            <ForeName>Li</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Biotherapy Center and Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Yu</LastName>
            <ForeName>Weina</ForeName>
            <Initials>W</Initials>
            <AffiliationInfo>
              <Affiliation>Biotherapy Center and Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Yi</ForeName>
            <Initials>Y</Initials>
            <Identifier Source="ORCID">0000-0001-9861-4681</Identifier>
            <AffiliationInfo>
              <Affiliation>Biotherapy Center and Cancer Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China. yizhang@zzu.edu.cn.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>School of Life Sciences, Zhengzhou University, Zhengzhou, 450001, China. yizhang@zzu.edu.cn.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Henan Key Laboratory for Tumor Immunology and Biotherapy, Zhengzhou, Henan, 450052, China. yizhang@zzu.edu.cn.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Esophageal Cancer Prevention &amp; Treatment, Zhengzhou University, Zhengzhou, 450052, China. yizhang@zzu.edu.cn.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>27</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Signal Transduct Target Ther</MedlineTA>
        <NlmUniqueID>101676423</NlmUniqueID>
        <ISSNLinking>2059-3635</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002454" MajorTopicYN="N">Cell Differentiation</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D060833" MajorTopicYN="N">Cellular Microenvironment</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D022423" MajorTopicYN="N">Myeloid Cells</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
          <QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059010" MajorTopicYN="N">Single-Cell Analysis</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>The authors declare no competing interests.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>8</Month>
          <Day>3</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>12</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>28</Day>
          <Hour>5</Hour>
          <Minute>52</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34707085</ArticleId>
        <ArticleId IdType="pmc">PMC8549428</ArticleId>
        <ArticleId IdType="doi">10.1038/s41392-021-00792-0</ArticleId>
        <ArticleId IdType="pii">10.1038/s41392-021-00792-0</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Sette A, Crotty S. Adaptive immunity to SARS-CoV-2 and COVID-19. Cell. 2021;184:861–880. doi: 10.1016/j.cell.2021.01.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2021.01.007</ArticleId>
            <ArticleId IdType="pmc">PMC7803150</ArticleId>
            <ArticleId IdType="pubmed">33497610</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liao M, et al.  Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. Nat. Med. 2020;26:842–844. doi: 10.1038/s41591-020-0901-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41591-020-0901-9</ArticleId>
            <ArticleId IdType="pubmed">32398875</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Veglia F, Perego M, Gabrilovich D. Myeloid-derived suppressor cells coming of age. Nat. Immunol. 2018;19:108–119. doi: 10.1038/s41590-017-0022-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41590-017-0022-x</ArticleId>
            <ArticleId IdType="pmc">PMC5854158</ArticleId>
            <ArticleId IdType="pubmed">29348500</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim IS, et al.  Immuno-subtyping of breast cancer reveals distinct myeloid cell profiles and immunotherapy resistance mechanisms. Nat. Cell Biol. 2019;21:1113–1126. doi: 10.1038/s41556-019-0373-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41556-019-0373-7</ArticleId>
            <ArticleId IdType="pmc">PMC6726554</ArticleId>
            <ArticleId IdType="pubmed">31451770</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim N, et al.  Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma. Nat. Commun. 2020;11:2285. doi: 10.1038/s41467-020-16164-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-020-16164-1</ArticleId>
            <ArticleId IdType="pmc">PMC7210975</ArticleId>
            <ArticleId IdType="pubmed">32385277</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Q, et al.  Landscape and dynamics of single immune cells in hepatocellular carcinoma. Cell. 2019;179:829–845 e820. doi: 10.1016/j.cell.2019.10.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2019.10.003</ArticleId>
            <ArticleId IdType="pubmed">31675496</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mann ER, et al.  Longitudinal immune profiling reveals key myeloid signatures associated with COVID-19. Sci. Immunol. 2020;17:14.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7857390</ArticleId>
            <ArticleId IdType="pubmed">32943497</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brodin P. Immune determinants of COVID-19 disease presentation and severity. Nat. Med. 2021;27:28–33. doi: 10.1038/s41591-020-01202-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41591-020-01202-8</ArticleId>
            <ArticleId IdType="pubmed">33442016</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McGonagle D, Ramanan AV, Bridgewood C. Immune cartography of macrophage activation syndrome in the COVID-19 era. Nat. Rev. Rheumatol. 2021;17:145–157. doi: 10.1038/s41584-020-00571-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41584-020-00571-1</ArticleId>
            <ArticleId IdType="pmc">PMC7863615</ArticleId>
            <ArticleId IdType="pubmed">33547426</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu K, et al.  Dysregulated adaptive immune response contributes to severe COVID-19. Cell Res. 2020;30:814–816. doi: 10.1038/s41422-020-0391-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41422-020-0391-9</ArticleId>
            <ArticleId IdType="pmc">PMC7403569</ArticleId>
            <ArticleId IdType="pubmed">32759967</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schulte-Schrepping J, et al.  Severe COVID-19 is marked by a dysregulated myeloid. Cell Compartment. Cell. 2020;182:1419–1440 e1423.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7405822</ArticleId>
            <ArticleId IdType="pubmed">32810438</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Veglia F, Sanseviero E, Gabrilovich DI. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. Nat. Rev. Immunol. 2021;21:485–498. doi: 10.1038/s41577-020-00490-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41577-020-00490-y</ArticleId>
            <ArticleId IdType="pmc">PMC7849958</ArticleId>
            <ArticleId IdType="pubmed">33526920</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 2009;9:162–174. doi: 10.1038/nri2506.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nri2506</ArticleId>
            <ArticleId IdType="pmc">PMC2828349</ArticleId>
            <ArticleId IdType="pubmed">19197294</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jakubzick CV, Randolph GJ, Henson PM. Monocyte differentiation and antigen-presenting functions. Nat. Rev. Immunol. 2017;17:349–362. doi: 10.1038/nri.2017.28.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nri.2017.28</ArticleId>
            <ArticleId IdType="pubmed">28436425</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Merad M, Martin JC. Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages. Nat. Rev. Immunol. 2020;20:355–362. doi: 10.1038/s41577-020-0331-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41577-020-0331-4</ArticleId>
            <ArticleId IdType="pmc">PMC7201395</ArticleId>
            <ArticleId IdType="pubmed">32376901</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stefano Ugel SC, De Sanctis F, Bronte AV. Monocytes in the tumor microenvironment. Annu. Rev. Pathol. Mech. Dis. 2021;16:30.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33497262</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shaath H, Vishnubalaji R, Elkord E, Alajez NM. Single-cell transcriptome analysis highlights a role for neutrophils and inflammatory macrophages in the pathogenesis of severe COVID-19. Cells. 2020;9:2374. doi: 10.3390/cells9112374.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cells9112374</ArticleId>
            <ArticleId IdType="pmc">PMC7693119</ArticleId>
            <ArticleId IdType="pubmed">33138195</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Payen D, et al.  A longitudinal study of immune cells in severe COVID-19 patients. Front. Immunol. 2020;11:580250. doi: 10.3389/fimmu.2020.580250.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2020.580250</ArticleId>
            <ArticleId IdType="pmc">PMC7597438</ArticleId>
            <ArticleId IdType="pubmed">33178207</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Parackova Z, et al.  Disharmonic inflammatory signatures in COVID-19: augmented neutrophils’ but impaired monocytes’ and dendritic cells’ responsiveness. Cells. 2020;9:2206. doi: 10.3390/cells9102206.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cells9102206</ArticleId>
            <ArticleId IdType="pmc">PMC7600406</ArticleId>
            <ArticleId IdType="pubmed">33003471</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Silvin A, et al.  Elevated calprotectin and abnormal myeloid cell subsets discriminate severe from mild COVID-19. Cell. 2020;182:1401–1418 e1418. doi: 10.1016/j.cell.2020.08.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2020.08.002</ArticleId>
            <ArticleId IdType="pmc">PMC7405878</ArticleId>
            <ArticleId IdType="pubmed">32810439</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang D, et al.  Frontline science: COVID-19 infection induces readily detectable morphologic and inflammation-related phenotypic changes in peripheral blood monocytes. J. Leukoc. Biol. 2021;109:13–22. doi: 10.1002/JLB.4HI0720-470R.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/JLB.4HI0720-470R</ArticleId>
            <ArticleId IdType="pmc">PMC7675546</ArticleId>
            <ArticleId IdType="pubmed">33040384</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kazancioglu S, et al.  Lymphocyte subset alteration and monocyte CD4 expression reduction in patients with severe COVID-19. Viral Immunol. 2020;34:342–351. doi: 10.1089/vim.2020.0166.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1089/vim.2020.0166</ArticleId>
            <ArticleId IdType="pubmed">33264073</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wauters E, et al.  Discriminating mild from critical COVID-19 by innate and adaptive immune single-cell profiling of bronchoalveolar lavages. Cell Res. 2021;31:272–290. doi: 10.1038/s41422-020-00455-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41422-020-00455-9</ArticleId>
            <ArticleId IdType="pmc">PMC8027624</ArticleId>
            <ArticleId IdType="pubmed">33473155</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Heming M, et al.  Neurological manifestations of COVID-19 feature T-cell exhaustion and dedifferentiated monocytes in cerebrospinal fluid. Immunity. 2021;54:164–175 e166. doi: 10.1016/j.immuni.2020.12.011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2020.12.011</ArticleId>
            <ArticleId IdType="pmc">PMC7831653</ArticleId>
            <ArticleId IdType="pubmed">33382973</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jaillon S, Ponzetta A, Mitri DD, Santoni A, Bonecchi R, Mantovani A. Neutrophil diversity and plasticity in tumour progression and therapy. Nat. Rev. Cancer. 2020;20:485–503. doi: 10.1038/s41568-020-0281-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41568-020-0281-y</ArticleId>
            <ArticleId IdType="pubmed">32694624</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Skendros P, et al.  Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis. J. Clin. Invest. 2020;130:6151–6157. doi: 10.1172/JCI141374.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI141374</ArticleId>
            <ArticleId IdType="pmc">PMC7598040</ArticleId>
            <ArticleId IdType="pubmed">32759504</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jimeno S, et al.  Prognostic implications of neutrophil-lymphocyte ratio in COVID-19. Eur. J. Clin. Invest. 2021;51:e13404. doi: 10.1111/eci.13404.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/eci.13404</ArticleId>
            <ArticleId IdType="pubmed">32918295</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Y, et al.  Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19. J. Infect. 2020;81:e6–e12.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7195072</ArticleId>
            <ArticleId IdType="pubmed">32283162</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ramos-Penafiel CO, et al.  Usefulness of the neutrophil-to-lymphocyte, monocyte-to-lymphocyte and lymphocyte-to-platelet ratios for the prognosis of COVID-19-associated complications. Gac. Med Mex. 2020;156:405–411.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">33372941</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nagarsheth N, Wicha MS, Zou W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat. Rev. Immunol. 2017;17:559–572. doi: 10.1038/nri.2017.49.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nri.2017.49</ArticleId>
            <ArticleId IdType="pmc">PMC5731833</ArticleId>
            <ArticleId IdType="pubmed">28555670</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huh SJ, Liang S, Sharma A, Dong C, Robertson GP. Transiently entrapped circulating tumor cells interact with neutrophils to facilitate lung metastasis development. Cancer Res. 2010;70:6071–6082. doi: 10.1158/0008-5472.CAN-09-4442.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-09-4442</ArticleId>
            <ArticleId IdType="pmc">PMC2905495</ArticleId>
            <ArticleId IdType="pubmed">20610626</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fridlender ZG, et al.  Polarization of tumor-associated neutrophil phenotype by TGF-β: “N1” versus “N2” TAN. Cancer Cell. 2009;16:183–194. doi: 10.1016/j.ccr.2009.06.017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccr.2009.06.017</ArticleId>
            <ArticleId IdType="pmc">PMC2754404</ArticleId>
            <ArticleId IdType="pubmed">19732719</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Casbon AJ, et al.  Invasive breast cancer reprograms early myeloid differentiation in the bone marrow to generate immunosuppressive neutrophils. Proc. Natl Acad. Sci. USA. 2015;112:E566–E575. doi: 10.1073/pnas.1424927112.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1424927112</ArticleId>
            <ArticleId IdType="pmc">PMC4330753</ArticleId>
            <ArticleId IdType="pubmed">25624500</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Waight JD, et al.  Myeloid-derived suppressor cell development is regulated by a STAT/IRF-8 axis. J. Clin. Invest. 2013;123:4464–4478. doi: 10.1172/JCI68189.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI68189</ArticleId>
            <ArticleId IdType="pmc">PMC3784535</ArticleId>
            <ArticleId IdType="pubmed">24091328</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aschenbrenner AC, et al.  Disease severity-specific neutrophil signatures in blood transcriptomes stratify COVID-19 patients. Genome Med. 2021;13:7. doi: 10.1186/s13073-020-00823-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13073-020-00823-5</ArticleId>
            <ArticleId IdType="pmc">PMC7805430</ArticleId>
            <ArticleId IdType="pubmed">33441124</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Agrati C, et al.  Expansion of myeloid-derived suppressor cells in patients with severe coronavirus disease (COVID-19) Cell Death Differ. 2020;27:3196–3207. doi: 10.1038/s41418-020-0572-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41418-020-0572-6</ArticleId>
            <ArticleId IdType="pmc">PMC7278239</ArticleId>
            <ArticleId IdType="pubmed">32514047</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Falck-Jones S, et al.  Functional monocytic myeloid-derived suppressor cells increase in blood but not airways and predict COVID-19 severity. J. Clin. Invest. 2021;131:e144734. doi: 10.1172/JCI144734.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI144734</ArticleId>
            <ArticleId IdType="pmc">PMC7954608</ArticleId>
            <ArticleId IdType="pubmed">33492309</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marvel D, Gabrilovich DI. Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected. J. Clin. Invest. 2015;125:3356–3364. doi: 10.1172/JCI80005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI80005</ArticleId>
            <ArticleId IdType="pmc">PMC4588239</ArticleId>
            <ArticleId IdType="pubmed">26168215</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kumar V, Patel S, Tcyganov E, Gabrilovich DI. The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends Immunol. 2016;37:208–220. doi: 10.1016/j.it.2016.01.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.it.2016.01.004</ArticleId>
            <ArticleId IdType="pmc">PMC4775398</ArticleId>
            <ArticleId IdType="pubmed">26858199</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Adah D, et al.  Implications of MDSCs-targeting in lung cancer chemo-immunotherapeutics. Pharm. Res. 2016;110:25–34. doi: 10.1016/j.phrs.2016.05.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.phrs.2016.05.007</ArticleId>
            <ArticleId IdType="pubmed">27157248</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tobin RP, Davis D, Jordan KR, McCarter MD. The clinical evidence for targeting human myeloid-derived suppressor cells in cancer patients. J. Leukoc. Biol. 2017;102:381–391. doi: 10.1189/jlb.5VMR1016-449R.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1189/jlb.5VMR1016-449R</ArticleId>
            <ArticleId IdType="pmc">PMC6608076</ArticleId>
            <ArticleId IdType="pubmed">28179538</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Okla K, et al.  Clinical relevance and immunosuppressive pattern of circulating and infiltrating subsets of myeloid-derived suppressor cells (MDSCs) in epithelial ovarian cancer. Front. Immunol. 2019;10:691. doi: 10.3389/fimmu.2019.00691.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2019.00691</ArticleId>
            <ArticleId IdType="pmc">PMC6456713</ArticleId>
            <ArticleId IdType="pubmed">31001284</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tavazoie MF, et al.  LXR/ApoE activation restricts innate immune suppression in cancer. Cell. 2018;172:825–840 e818. doi: 10.1016/j.cell.2017.12.026.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2017.12.026</ArticleId>
            <ArticleId IdType="pmc">PMC5846344</ArticleId>
            <ArticleId IdType="pubmed">29336888</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Highfill SL, et al.  Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy. Sci. Transl. Med. 2014;6:237ra267. doi: 10.1126/scitranslmed.3007974.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scitranslmed.3007974</ArticleId>
            <ArticleId IdType="pmc">PMC6980372</ArticleId>
            <ArticleId IdType="pubmed">24848257</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kaneda MM, et al.  PI3Kgamma is a molecular switch that controls immune suppression. Nature. 2016;539:437–442. doi: 10.1038/nature19834.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature19834</ArticleId>
            <ArticleId IdType="pmc">PMC5479689</ArticleId>
            <ArticleId IdType="pubmed">27642729</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bottazzi B, Doni A, Garlanda C, Mantovani A. An integrated view of humoral innate immunity: pentraxins as a paradigm. Annu. Rev. Immunol. 2010;28:157–183. doi: 10.1146/annurev-immunol-030409-101305.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev-immunol-030409-101305</ArticleId>
            <ArticleId IdType="pubmed">19968561</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brunetta E, et al.  Macrophage expression and prognostic significance of the long pentraxin PTX3 in COVID-19. Nat. Immunol. 2021;22:19–24. doi: 10.1038/s41590-020-00832-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41590-020-00832-x</ArticleId>
            <ArticleId IdType="pubmed">33208929</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wilk AJ, et al.  A single-cell atlas of the peripheral immune response in patients with severe COVID-19. Nat. Med. 2020;26:1070–1076. doi: 10.1038/s41591-020-0944-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41591-020-0944-y</ArticleId>
            <ArticleId IdType="pmc">PMC7382903</ArticleId>
            <ArticleId IdType="pubmed">32514174</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bedin AS, et al.  Monocyte CD169 expression as a biomarker in the early diagnosis of coronavirus disease 2019. J. Infect. Dis. 2021;223:562–567. doi: 10.1093/infdis/jiaa724.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/infdis/jiaa724</ArticleId>
            <ArticleId IdType="pmc">PMC7717347</ArticleId>
            <ArticleId IdType="pubmed">33206973</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ait Belkacem I, et al.  Cell analysis from dried blood spots: new opportunities in immunology, hematology, and infectious diseases. Adv. Sci. 2021;8:2100323. doi: 10.1002/advs.202100323.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/advs.202100323</ArticleId>
            <ArticleId IdType="pmc">PMC8456206</ArticleId>
            <ArticleId IdType="pubmed">34278739</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim H, Seed B. The transcription factor MafB antagonizes antiviral responses by blocking recruitment of coactivators to the transcription factor IRF3. Nat. Immunol. 2010;11:743–750. doi: 10.1038/ni.1897.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ni.1897</ArticleId>
            <ArticleId IdType="pmc">PMC3050627</ArticleId>
            <ArticleId IdType="pubmed">20581830</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vega MA, et al.  MAFB and MAF transcription factors as macrophage checkpoints for COVID-19 severity. Front. Immunol. 2020;11:603507. doi: 10.3389/fimmu.2020.603507.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2020.603507</ArticleId>
            <ArticleId IdType="pmc">PMC7708330</ArticleId>
            <ArticleId IdType="pubmed">33312178</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mehta P, et al.  Therapeutic blockade of granulocyte macrophage colony-stimulating factor in COVID-19-associated hyperinflammation: challenges and opportunities. Lancet Respir. Med. 2020;8:822–830. doi: 10.1016/S2213-2600(20)30267-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S2213-2600(20)30267-8</ArticleId>
            <ArticleId IdType="pmc">PMC7834476</ArticleId>
            <ArticleId IdType="pubmed">32559419</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gibellini L, et al.  Altered bioenergetics and mitochondrial dysfunction of monocytes in patients with COVID-19 pneumonia. EMBO Mol. Med. 2020;12:e13001. doi: 10.15252/emmm.202013001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.15252/emmm.202013001</ArticleId>
            <ArticleId IdType="pmc">PMC7645870</ArticleId>
            <ArticleId IdType="pubmed">33078545</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhou Z, et al.  Heightened innate immune responses in the respiratory tract of COVID-19 patients. Cell Host Microbe. 2020;27:883–890 e882. doi: 10.1016/j.chom.2020.04.017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.chom.2020.04.017</ArticleId>
            <ArticleId IdType="pmc">PMC7196896</ArticleId>
            <ArticleId IdType="pubmed">32407669</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Didangelos A. COVID-19 hyperinflammation: what about neutrophils? mSphere. 2020;5:e00367–20. doi: 10.1128/mSphere.00367-20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/mSphere.00367-20</ArticleId>
            <ArticleId IdType="pmc">PMC7316488</ArticleId>
            <ArticleId IdType="pubmed">32581077</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Neelapu SS, et al.  Chimeric antigen receptor T-cell therapy - assessment and management of toxicities. Nat. Rev. Clin. Oncol. 2018;15:47–62. doi: 10.1038/nrclinonc.2017.148.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrclinonc.2017.148</ArticleId>
            <ArticleId IdType="pmc">PMC6733403</ArticleId>
            <ArticleId IdType="pubmed">28925994</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carl RSOC, June H, Omkar U, Saba Ghassemi K, Milone MC. CAR T cell immunotherapy for human cancer. Science. 2018;359:5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">29567707</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guo C, et al.  Single-cell analysis of two severe COVID-19 patients reveals a monocyte-associated and tocilizumab-responding cytokine storm. Nat. Commun. 2020;11:3924. doi: 10.1038/s41467-020-17834-w.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-020-17834-w</ArticleId>
            <ArticleId IdType="pmc">PMC7413381</ArticleId>
            <ArticleId IdType="pubmed">32764665</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang L, et al.  Sepsis-associated severe interleukin-6 storm in critical coronavirus disease 2019. Cell Mol. Immunol. 2020;17:1092–1094. doi: 10.1038/s41423-020-00522-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41423-020-00522-6</ArticleId>
            <ArticleId IdType="pmc">PMC7484610</ArticleId>
            <ArticleId IdType="pubmed">32917983</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Demers M, et al.  Cancers predispose neutrophils to release extracellular DNA traps that contribute to cancer-associated thrombosis. Proc. Natl Acad. Sci. USA. 2012;109:13076–13081. doi: 10.1073/pnas.1200419109.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1200419109</ArticleId>
            <ArticleId IdType="pmc">PMC3420209</ArticleId>
            <ArticleId IdType="pubmed">22826226</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alfaro C, et al.  Tumor-produced interleukin-8 attracts human myeloid-derived suppressor cells and elicits extrusion of neutrophil extracellular traps (NETs) Clin. Cancer Res. 2016;22:3924–3936. doi: 10.1158/1078-0432.CCR-15-2463.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-15-2463</ArticleId>
            <ArticleId IdType="pubmed">26957562</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang J, et al.  Excessive neutrophils and neutrophil extracellular traps in COVID-19. Front. Immunol. 2020;11:2063. doi: 10.3389/fimmu.2020.02063.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2020.02063</ArticleId>
            <ArticleId IdType="pmc">PMC7461898</ArticleId>
            <ArticleId IdType="pubmed">33013872</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Veras FP, et al.  SARS-CoV-2-triggered neutrophil extracellular traps mediate COVID-19 pathology. J. Exp. Med. 2020;217:e20201129. doi: 10.1084/jem.20201129.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1084/jem.20201129</ArticleId>
            <ArticleId IdType="pmc">PMC7488868</ArticleId>
            <ArticleId IdType="pubmed">32926098</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Middleton EA, et al.  Neutrophil extracellular traps (NETs) contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome. Blood. 2020;136:1169–1179. doi: 10.1182/blood.2020007008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood.2020007008</ArticleId>
            <ArticleId IdType="pmc">PMC7472714</ArticleId>
            <ArticleId IdType="pubmed">32597954</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Radermecker C, et al.  Neutrophil extracellular traps infiltrate the lung airway, interstitial, and vascular compartments in severe COVID-19. J. Exp. Med. 2020;217:e20201012. doi: 10.1084/jem.20201012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1084/jem.20201012</ArticleId>
            <ArticleId IdType="pmc">PMC7488867</ArticleId>
            <ArticleId IdType="pubmed">32926097</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xie X, et al.  Single-cell transcriptome profiling reveals neutrophil heterogeneity in homeostasis and infection. Nat. Immunol. 2020;21:1119–1133. doi: 10.1038/s41590-020-0736-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41590-020-0736-z</ArticleId>
            <ArticleId IdType="pmc">PMC7442692</ArticleId>
            <ArticleId IdType="pubmed">32719519</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Laforge M, et al.  Tissue damage from neutrophil-induced oxidative stress in COVID-19. Nat. Rev. Immunol. 2020;20:515–516. doi: 10.1038/s41577-020-0407-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41577-020-0407-1</ArticleId>
            <ArticleId IdType="pmc">PMC7388427</ArticleId>
            <ArticleId IdType="pubmed">32728221</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Parackova Z, Bloomfield M, Klocperk A, Sediva A. Neutrophils mediate Th17 promotion in COVID-19 patients. J. Leukoc. Biol. 2021;109:73–76. doi: 10.1002/JLB.4COVCRA0820-481RRR.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/JLB.4COVCRA0820-481RRR</ArticleId>
            <ArticleId IdType="pmc">PMC7753339</ArticleId>
            <ArticleId IdType="pubmed">33289169</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen Y, et al.  Aging in COVID-19: vulnerability, immunity and intervention. Ageing Res. Rev. 2021;65:101205. doi: 10.1016/j.arr.2020.101205.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.arr.2020.101205</ArticleId>
            <ArticleId IdType="pmc">PMC7604159</ArticleId>
            <ArticleId IdType="pubmed">33137510</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takahashi T, et al.  Sex differences in immune responses that underlie COVID-19 disease outcomes. Nature. 2020;588:315–320. doi: 10.1038/s41586-020-2700-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-020-2700-3</ArticleId>
            <ArticleId IdType="pmc">PMC7725931</ArticleId>
            <ArticleId IdType="pubmed">32846427</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Codo AC, et al.  Elevated glucose levels favor SARS-CoV-2 infection and monocyte response through a HIF-1alpha/glycolysis-dependent axis. Cell Metab. 2020;32:437–446 e435. doi: 10.1016/j.cmet.2020.07.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cmet.2020.07.007</ArticleId>
            <ArticleId IdType="pmc">PMC7367032</ArticleId>
            <ArticleId IdType="pubmed">32697943</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang L, et al.  COVID-19: immunopathogenesis and immunotherapeutics. Signal Transduct. Target Ther. 2020;5:128. doi: 10.1038/s41392-020-00243-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41392-020-00243-2</ArticleId>
            <ArticleId IdType="pmc">PMC7381863</ArticleId>
            <ArticleId IdType="pubmed">32712629</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mazzoni A, et al.  Impaired immune cell cytotoxicity in severe COVID-19 is IL-6 dependent. J. Clin. Invest. 2020;130:4694–4703. doi: 10.1172/JCI138554.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI138554</ArticleId>
            <ArticleId IdType="pmc">PMC7456250</ArticleId>
            <ArticleId IdType="pubmed">32463803</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao X, Zhang Y. Mesenchymal stem cells represent a potential therapeutic option for coronavirus disease 2019-related acute respiratory distress syndrome. Engineering (Beijing) 2020;6:1073–1075.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7284238</ArticleId>
            <ArticleId IdType="pubmed">32837745</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schalper KA, et al.  Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors. Nat. Med. 2020;26:688–692. doi: 10.1038/s41591-020-0856-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41591-020-0856-x</ArticleId>
            <ArticleId IdType="pmc">PMC8127102</ArticleId>
            <ArticleId IdType="pubmed">32405062</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bilusic M, et al.  Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors. J. Immunother. Cancer. 2019;7:240. doi: 10.1186/s40425-019-0706-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-019-0706-x</ArticleId>
            <ArticleId IdType="pmc">PMC6729083</ArticleId>
            <ArticleId IdType="pubmed">31488216</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>The REMAP-CAP Investigators. Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19. N. Engl. J. Med. 384, 1491–1502 (2021).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7953461</ArticleId>
            <ArticleId IdType="pubmed">33631065</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) working group, et al.  Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis. JAMA. 2021;326:499–518. doi: 10.1001/jama.2021.11330.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.2021.11330</ArticleId>
            <ArticleId IdType="pmc">PMC8261689</ArticleId>
            <ArticleId IdType="pubmed">34228774</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Guimaraes PO, et al.  Tofacitinib in patients hospitalized with Covid-19 pneumonia. N. Engl. J. Med. 2021;385:406–415. doi: 10.1056/NEJMoa2101643.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa2101643</ArticleId>
            <ArticleId IdType="pmc">PMC8220898</ArticleId>
            <ArticleId IdType="pubmed">34133856</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Caricchio R, et al.  Effect of Canakinumab vs placebo on survival without invasive mechanical ventilation in patients hospitalized with severe COVID-19: a randomized clinical trial. JAMA. 2021;326:230–239. doi: 10.1001/jama.2021.9508.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.2021.9508</ArticleId>
            <ArticleId IdType="pmc">PMC8293025</ArticleId>
            <ArticleId IdType="pubmed">34283183</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shida Y, Cooper PR, Potter SL, Mueck B, Jarai G. Cloning and expression analysis of a novel G-protein-coupled receptor selectively expressed on granulocytes. J. Leukoc. Biol. 2001;69:1045–1052.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11404393</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Suzuki M, et al.  Medium-chain fatty acid-sensing receptor, GPR84, is a proinflammatory receptor. J. Biol. Chem. 2013;288:10684–10691. doi: 10.1074/jbc.M112.420042.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/jbc.M112.420042</ArticleId>
            <ArticleId IdType="pmc">PMC3624448</ArticleId>
            <ArticleId IdType="pubmed">23449982</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vanhoutte E, et al.  Human safety, pharmacokinetics and pharmacodynamics of the GPR84 antagonist GLPG1205, a potential new approach to treat IBD. J. Crohn Colitis. 2015;9:S387.</Citation>
        </Reference>
        <Reference>
          <Citation>Li Y, et al.  Fatty acid receptor modulator PBI-4050 inhibits kidney fibrosis and improves glycemic control. JCI Insight. 2018;3:e120365. doi: 10.1172/jci.insight.120365.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/jci.insight.120365</ArticleId>
            <ArticleId IdType="pmc">PMC6012516</ArticleId>
            <ArticleId IdType="pubmed">29769449</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Washburn ML, Crosby R, Remlinger K, Wang F, Creech D. Therapeutically attenuating neutrophil recruitment with a CXCR2 antagonist in combination with oseltamivir ameliorates influenza-induced lung injury and disease. Open Forum Infect. Dis. 2019;6:ofz106. doi: 10.1093/ofid/ofz106.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/ofid/ofz106</ArticleId>
            <ArticleId IdType="pmc">PMC6483135</ArticleId>
            <ArticleId IdType="pubmed">31041337</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tomar B, Anders HJ, Desai J, Mulay SR. Neutrophils and neutrophil extracellular traps drive necroinflammation in COVID-19. Cells. 2020;9:1383. doi: 10.3390/cells9061383.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cells9061383</ArticleId>
            <ArticleId IdType="pmc">PMC7348784</ArticleId>
            <ArticleId IdType="pubmed">32498376</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stone JH, et al.  Efficacy of Tocilizumab in patients hospitalized with Covid-19. N. Engl. J. Med. 2020;383:2333–2344. doi: 10.1056/NEJMoa2028836.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa2028836</ArticleId>
            <ArticleId IdType="pmc">PMC7646626</ArticleId>
            <ArticleId IdType="pubmed">33085857</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Paul AA, Cremer C. Mavrilimumab in patients with severe COVID-19 pneumonia and systemic hyperinflammation (MASH-COVID): an investigator initiated, multicentre, double-blind, randomised, placebo-controlled trial. Lancet Rheumatol. 2021;3:9. doi: 10.1016/S2665-9913(20)30392-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S2665-9913(20)30392-1</ArticleId>
            <ArticleId IdType="pmc">PMC7969143</ArticleId>
            <ArticleId IdType="pubmed">33754144</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kreuzberger N, et al.  SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. Cochrane Database Syst. Rev. 2021;9:CD013825.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8411904</ArticleId>
            <ArticleId IdType="pubmed">34473343</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Marconi, C. et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. The Lancet Respiratory Medicine (2021).</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8409066</ArticleId>
            <ArticleId IdType="pubmed">34480861</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Azzi Y, Bartash R, Scalea J, Loarte-Campos P, Akalin E. COVID-19 and solid organ transplantation: a review article. Transplantation. 2021;105:37–55. doi: 10.1097/TP.0000000000003523.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/TP.0000000000003523</ArticleId>
            <ArticleId IdType="pubmed">33148977</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kalil AC, et al.  Baricitinib plus Remdesivir for hospitalized adults with Covid-19. N. Engl. J. Med. 2021;384:795–807. doi: 10.1056/NEJMoa2031994.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa2031994</ArticleId>
            <ArticleId IdType="pmc">PMC7745180</ArticleId>
            <ArticleId IdType="pubmed">33306283</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Caricchio R, et al.  Effect of Canakinumab vs placebo on survival without invasive mechanical ventilation in patients hospitalized with severe COVID-19: a randomized clinical trial. JAMA. 2021;326:230–239. doi: 10.1001/jama.2021.9508.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.2021.9508</ArticleId>
            <ArticleId IdType="pmc">PMC8293025</ArticleId>
            <ArticleId IdType="pubmed">34283183</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
